H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Frequently asked questions
What sector does H. LUNDBECK A/S SER.B DK1 (LDBA) operate in?
H. LUNDBECK A/S SER.B DK1 belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is H. LUNDBECK A/S SER.B DK1 (LDBA) current stock price?
As of the latest data, H. LUNDBECK A/S SER.B DK1 stock price is €7.05, with a previous close of €6.83. H. LUNDBECK A/S SER.B DK1 gained €0.22 in the last trading session, representing a 3.22% increase.
What is H. LUNDBECK A/S SER.B DK1 (LDBA) current market capitalization?
H. LUNDBECK A/S SER.B DK1 market cap is approximately 5.59 billion.
What is H. LUNDBECK A/S SER.B DK1 (LDBA) Earnings Per Share (EPS)?
The trailing EPS is €0.53.
What is H. LUNDBECK A/S SER.B DK1 (LDBA) Price-to-Earnings (P/E) ratio?
H. LUNDBECK A/S SER.B DK1 current P/E ratio is 13.3.
Does H. LUNDBECK A/S SER.B DK1 (LDBA) pay dividends?
Yes. H. LUNDBECK A/S SER.B DK1 pays annual dividends with an annualized yield of 0.29% and an estimated annual payout of €0.15 per share.
When is the next ex-dividend date for H. LUNDBECK A/S SER.B DK1 (LDBA)?
The next ex-dividend date is scheduled for March 19, 2027.
When is H. LUNDBECK A/S SER.B DK1 (LDBA) next earnings report?
H. LUNDBECK A/S SER.B DK1 is expected to release its next earnings report on September 30, 2026.
What is H. LUNDBECK A/S SER.B DK1 (LDBA) beta (volatility) score?
H. LUNDBECK A/S SER.B DK1 has a beta of 0.257, indicating lower volatility than the overall market.
